Drug intelligence / Profile preview

SW-01-LKPC

Development stage: Preclinical
Lead developer: Shandong Lukang Pharmaceutical
Modality: Recombinant Proteins and Enzymes

Overview

SW-01-LKPC is an investigational biologic drug candidate being developed by Liaoning Kelong Pharmaceutical (LKPC). Classified in Chinese regulatory filings as a "Class 1 Therapeutic Biological Product," it is identified as a recombinant protein intended for the treatment of oncology indications (anti-tumor therapy). Publicly available information regarding the drug is extremely limited, as the compound has primarily surfaced through corporate procurement notices and environmental impact assessments related to LKPC's manufacturing facilities. As of early 2024, specific details regarding its molecular target, mechanism of action, and current clinical development phase have not been officially disclosed by the developer.

Beyond the preview

Go deeper on SW-01-LKPC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SW-01-LKPC.

Explore the full profile